203 related articles for article (PubMed ID: 30901076)
1. Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.
Nabieva N; Häberle L; Brucker SY; Janni W; Volz B; Loehberg CR; Hartkopf AD; Walter CB; Baake G; Fridman A; Malter W; Wuerstlein R; Harbeck N; Hoffmann O; Kuemmel S; Martin B; Thomssen C; Graf H; Wolf C; Lux MP; Bayer CM; Rauh C; Hack CC; Almstedt K; Gass P; Heindl F; Brodkorb T; Lindner C; Kolberg HC; Krabisch P; Weigel M; Steinfeld-Birg D; Kohls A; Brucker C; Schulz V; Fischer G; Pelzer V; Rack B; Beckmann MW; Fehm T; Rody A; Maass N; Hein A; Fasching PA
Int J Cancer; 2019 Oct; 145(8):2114-2121. PubMed ID: 30901076
[TBL] [Abstract][Full Text] [Related]
2. Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
Hack CC; Häberle L; Brucker SY; Janni W; Volz B; Loehberg CR; Hartkopf AD; Walter CB; Baake G; Fridman A; Malter W; Wuerstlein R; Harbeck N; Hoffmann O; Kuemmel S; Martin B; Thomssen C; Graf H; Wolf C; Lux MP; Bayer CM; Rauh C; Almstedt K; Gass P; Heindl F; Brodkorb T; Willer L; Lindner C; Kolberg HC; Krabisch P; Weigel M; Steinfeld-Birg D; Kohls A; Brucker C; Schulz V; Fischer G; Pelzer V; Rack B; Beckmann MW; Fehm T; Rody A; Maass N; Hein A; Fasching PA; Nabieva N
Breast; 2020 Apr; 50():11-18. PubMed ID: 31958661
[TBL] [Abstract][Full Text] [Related]
3. Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.
Hershman DL; Unger JM; Crew KD; Awad D; Dakhil SR; Gralow J; Greenlee H; Lew DL; Minasian LM; Till C; Wade JL; Meyskens FL; Moinpour CM
J Clin Oncol; 2015 Jun; 33(17):1910-7. PubMed ID: 25940724
[TBL] [Abstract][Full Text] [Related]
4. Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
Nabieva N; Fehm T; Häberle L; de Waal J; Rezai M; Baier B; Baake G; Kolberg HC; Guggenberger M; Warm M; Harbeck N; Wuerstlein R; Deuker JU; Dall P; Richter B; Wachsmann G; Brucker C; Siebers JW; Popovic M; Kuhn T; Wolf C; Vollert HW; Breitbach GP; Janni W; Landthaler R; Kohls A; Rezek D; Noesselt T; Fischer G; Henschen S; Praetz T; Heyl V; Kühn T; Krauss T; Thomssen C; Hohn A; Tesch H; Mundhenke C; Hein A; Hack CC; Schmidt K; Belleville E; Brucker SY; Kümmel S; Beckmann MW; Wallwiener D; Hadji P; Fasching PA
Eur J Cancer; 2018 Jun; 96():82-90. PubMed ID: 29679775
[TBL] [Abstract][Full Text] [Related]
5. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kalaivani S; Devi J; Damodaran SE; Pradhan SC; Dubashi B; Dkhar SA; Adithan C
Breast Cancer Res Treat; 2020 Jul; 182(1):147-158. PubMed ID: 32385792
[TBL] [Abstract][Full Text] [Related]
6. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
[TBL] [Abstract][Full Text] [Related]
7. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
[TBL] [Abstract][Full Text] [Related]
8. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
Khan QJ; Kimler BF; Reddy PS; Sharma P; Klemp JR; Nydegger JL; Yeh HW; Fabian CJ
Breast Cancer Res Treat; 2017 Nov; 166(2):491-500. PubMed ID: 28770449
[TBL] [Abstract][Full Text] [Related]
11. Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study.
Wallwiener M; Nabieva N; Feisst M; Fehm T; de Waal J; Rezai M; Baier B; Baake G; Kolberg HC; Guggenberger M; Warm M; Harbeck N; Wuerstlein R; Deuker JU; Dall P; Richter B; Wachsmann G; Brucker C; Siebers JW; Popovic M; Kuhn T; Wolf C; Vollert HW; Breitbach GP; Janni W; Landthaler R; Kohls A; Rezek D; Noesselt T; Fischer G; Henschen S; Praetz T; Heyl V; Kühn T; Krauss T; Thomssen C; Hohn A; Tesch H; Mundhenke C; Hein A; Rauh C; Bayer CM; Schmidt K; Belleville E; Brucker SY; Hadji P; Beckmann MW; Wallwiener D; Kümmel S; Hartkopf A; Fasching PA
BMC Cancer; 2019 Jun; 19(1):611. PubMed ID: 31227025
[TBL] [Abstract][Full Text] [Related]
12. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
Swenson KK; Nissen MJ; Henly SJ; Maybon L; Pupkes J; Zwicky K; Tsai ML; Shapiro AC
Oncol Nurs Forum; 2013 Nov; 40(6):549-57. PubMed ID: 24161633
[TBL] [Abstract][Full Text] [Related]
13. Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.
Hershman DL; Unger JM; Greenlee H; Capodice JL; Lew DL; Darke AK; Kengla AT; Melnik MK; Jorgensen CW; Kreisle WH; Minasian LM; Fisch MJ; Henry NL; Crew KD
JAMA; 2018 Jul; 320(2):167-176. PubMed ID: 29998338
[TBL] [Abstract][Full Text] [Related]
14. A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms.
Helzlsouer KJ; Gallicchio L; MacDonald R; Wood B; Rushovich E
Breast Cancer Res Treat; 2012 Jan; 131(1):277-85. PubMed ID: 21904883
[TBL] [Abstract][Full Text] [Related]
15. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Borrie AE; Rose FA; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Teft WA; Kim RB
Breast Cancer Res Treat; 2020 Sep; 183(2):365-372. PubMed ID: 32632513
[TBL] [Abstract][Full Text] [Related]
16. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Gallicchio L; Macdonald R; Wood B; Rushovich E; Helzlsouer KJ
Breast Cancer Res Treat; 2011 Nov; 130(2):569-77. PubMed ID: 21647676
[TBL] [Abstract][Full Text] [Related]
17. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
[TBL] [Abstract][Full Text] [Related]
18. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.
Martínez N; Herrera M; Frías L; Provencio M; Pérez-Carrión R; Díaz V; Morse M; Crespo MC
Clin Transl Oncol; 2019 Apr; 21(4):489-498. PubMed ID: 30293230
[TBL] [Abstract][Full Text] [Related]
19. Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
Blok EJ; Kroep JR; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Putter H; Liefers GJ; Nortier JWR; Rutgers EJT; Seynaeve CM; van de Velde CJH;
Eur J Cancer; 2018 May; 95():59-67. PubMed ID: 29635145
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
